Results 171 to 180 of about 84,264 (300)

Phosphodiesterase inhibitors for the management of lower urinary tract symptoms in men without benign prostatic hyperplasia: a systematic review. [PDF]

Transl Androl Urol
Bakhsh A, Rajih E, Barayan GA, Garah E, Khan I, Alrehaili Z, Alhejaili S, Almuways M, Aloufi T, Alnazawi H, Alharbi A, Farghal D, Badawi A.   +12 more
europepmc   +1 more source

Is There a Causal Link Between GLP‐1 Receptor Agonists and Non‐Arteritic Anterior Ischaemic Optic Neuropathy? A Critique of the Clinical Evidence

Clinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are widely used for managing Type 2 diabetes and obesity, with well‐documented and significant cardiometabolic benefits. Recent observational reports and pharmacovigilance data have raised concerns about a possible association between GLP‐1RAs‐particularly semaglutide‐ and non‐arteritic ...
Helen V. Danesh‐Meyer, Joseph F. Rizzo III   +1 more
wiley   +1 more source

The Emerging Role of Phosphodiesterase Inhibitors in Fragile X Syndrome and Autism Spectrum Disorder. [PDF]

Pharmaceuticals (Basel)
Thomas SD, Mohammed HA, Hamad MIK, Oz M, Statsenko Y, Sadek B.   +5 more
europepmc   +1 more source

Cyclic AMP-hydrolyzing phosphodiesterase inhibitors potentiate statin-induced cancer cell death. [PDF]

Mol Oncol, 2020
Longo J, Pandyra AA, Stachura P, Minden MD, Schimmer AD, Penn LZ.   +5 more
europepmc   +1 more source

Steroidogenic compensation and lipid deficiency with enhanced NAD+ salvage in small‐for‐gestational‐age placenta

The FEBS Journal, EarlyView.
Fetal growth restriction is associated with placental metabolic adaptations. In small‐for‐gestational‐age placenta (SGA), cholesterol receptors and steroidogenic enzymes are upregulated, enhancing steroidogenesis. NAD salvage pathway is also increased to support NADP+/NADPH requirements.
Serena Xodo, Lorenza Driul, Vanessa Tolotto, Eros Di Giorgio, Luigi E. Xodo   +4 more
wiley   +1 more source

Neuroprotective Effects of Phosphodiesterase Inhibitors on Sestrin-2 (SESN2) Expression and Autophagy in Alzheimer's Disease Model. [PDF]

Cureus
Faikoglu G, Saygisever-Faikoglu K, Ozbasak H, Ugur SA, Uskur T, Akkan AG, Kelicen-Ugur P, Ozyazgan S.   +7 more
europepmc   +1 more source

Therapeutic Potential of Phosphodiesterase Inhibitors against Neurodegeneration: The Perspective of the Medicinal Chemist. [PDF]

ACS Chem Neurosci, 2020
Ribaudo G, Ongaro A, Zagotto G, Memo M, Gianoncelli A.   +4 more
europepmc   +1 more source

Potential Cancer- and Alzheimer's Disease-Targeting Phosphodiesterase Inhibitors from Uvaria alba: Insights from In Vitro and Consensus Virtual Screening. [PDF]

ACS Omega, 2021
Quimque MT, Notarte KI, Letada A, Fernandez RA, Pilapil DY, Pueblos KR, Agbay JC, Dahse HM, Wenzel-Storjohann A, Tasdemir D, Khan A, Wei DQ, Gose Macabeo AP.   +12 more
europepmc   +1 more source

Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trial

Journal of the European Academy of Dermatology and Venereology, EarlyView.
In this Phase 3 trial of Japanese patients with moderate to severe PPP (NCT05174065), significantly more patients achieved PPPASI‐50 at Week 16 with apremilast versus placebo. Patient‐reported outcomes, including pruritus and pain/discomfort, also showed significantly greater decreases at Week 16 with apremilast versus placebo.
Tadashi Terui, Yukari Okubo, Satomi Kobayashi, Akimichi Morita, Shinichi Imafuku, Yayoi Tada, Masatoshi Abe, Bruce Strober, Melinda Gooderham, Wendy Zhang, Junichiro Shimauchi, Masafumi Yaguchi, Takeshi Kimura, Ryuichi Ogawa, Hamid Amouzadeh, Masamoto Murakami   +15 more
wiley   +1 more source

Back to phosphodiesterase inhibitors for liver disease: Are we ready for clinical trials? [PDF]

Hepatology
Gobejishvili L, McClain CJ.
europepmc   +1 more source